July 24, 2020 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
4. Announcement: New Preferred Drug List (PDL) Classes for October Drug Utilization Review (DUR) Board Meeting
4. Announcement: New Preferred Drug List (PDL) Classes for October Drug Utilization Review (DUR) Board Meeting
»
2. Approval of minutes from May 22, 2020 (vote required)
2. Approval of minutes from May 22, 2020 (vote required)
»
3. Chair and Vice-Chair Election (vote required)
3. Chair and Vice-Chair Election (vote required)
»
5. Public comment on drug classes to be reviewed for the Medicaid (PDL): » - a. Alzheimer’s agents b. Antihistamines, minimally sedating c. Antihypertensives, sympatholytics d. Antimigraine agents, other e. Calcium channel blockers f. Cephalosporins and related antibiotics g. Cytokine and cell adhesion module antagonists h. Fluoroquinolones, oral i. Glucocorticoids, oral j. Immunosuppressives, oral k. Iron, oral l. Leukotriene modifiers m. Non-steroidal anti-inflammatory drugs (NSAIDs) n. Ophthalmic antibiotics o. Ophthalmic antibiotic-steroid combinations p. Ophthalmic for allergic conjunctivitis q. Ophthalmic, anti-inflammatories r. Ophthalmic, anti-inflammatories/immunomodulator s. Ophthalmic, glaucoma agents t. Otic antibiotics u. Otic anti-infectives and anesthetics v. Penicillins w. Progestational agents x. Rosacea agents, topical y. Skeletal muscle relaxants z. Steroids, topical aa. aa.Ulcerative colitis agents 1. Palforzia Maintenance Sachet (Oral), Palforzia Titration Capsule (Oral) / Anti-allergens, oral 2. Caplyta (Oral) / Antipsychotics 3. Trijardy XR (Oral) / Hypoglycemics, incretin mimetics/enhancers 4. Riomet extended release Suspension (Oral) / Hypoglycemics, metformin 5. Hizentra Syringe (Subcutaneous) / Immune globulins 6. Nexletol (Oral) / Lipotropics, other
5. Public comment on drug classes to be reviewed for the Medicaid (PDL): »
a. Alzheimer’s agents b. Antihistamines, minimally sedating
c. Antihypertensives, sympatholytics
d. Antimigraine agents, other
e. Calcium channel blockers
f. Cephalosporins and related antibiotics
g. Cytokine and cell adhesion module antagonists
h. Fluoroquinolones, oral
i. Glucocorticoids, oral
j. Immunosuppressives, oral
k. Iron, oral
l. Leukotriene modifiers
m. Non-steroidal anti-inflammatory drugs (NSAIDs)
n. Ophthalmic antibiotics
o. Ophthalmic antibiotic-steroid combinations
p. Ophthalmic for allergic conjunctivitis
q. Ophthalmic, anti-inflammatories
r. Ophthalmic, anti-inflammatories/immunomodulator
s. Ophthalmic, glaucoma agents
t. Otic antibiotics
u. Otic anti-infectives and anesthetics
v. Penicillins
w. Progestational agents
x. Rosacea agents, topical
y. Skeletal muscle relaxants
z. Steroids, topical
aa. aa.Ulcerative colitis agents
1. Palforzia Maintenance Sachet (Oral), Palforzia Titration Capsule (Oral) / Anti-allergens, oral
2. Caplyta (Oral) / Antipsychotics
3. Trijardy XR (Oral) / Hypoglycemics, incretin mimetics/enhancers
4. Riomet extended release Suspension (Oral) / Hypoglycemics, metformin
5. Hizentra Syringe (Subcutaneous) / Immune globulins
6. Nexletol (Oral) / Lipotropics, other
»
1. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
1. Therapeutic and clinical drug reviews and updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
»
2. Executive work session
2. Executive work session
»
3. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
3. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
»
4. Retrospective DUR: Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC » - a. Report on recent retrospective DUR interventions: i. Diabetes management ii. Attention-Deficit/Hyperactivity Disorder medication management b. Report on recent retrospective DUR intervention outcomes: i. Anticonvulsants drug use evaluation ii. Influenza Prevention iii. Cough and cold medication management in children c. Retrospective DUR proposals (vote required) i. Appropriate use of antibiotics ii. Contraceptives drug use evaluation iii. Gabapentinoids drug use evaluation
4. Retrospective DUR: Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC »
a. Report on recent retrospective DUR interventions: i. Diabetes management
ii. Attention-Deficit/Hyperactivity Disorder medication management
b. Report on recent retrospective DUR intervention outcomes:
i. Anticonvulsants drug use evaluation
ii. Influenza Prevention
iii. Cough and cold medication management in children
c. Retrospective DUR proposals (vote required)
i. Appropriate use of antibiotics
ii. Contraceptives drug use evaluation
iii. Gabapentinoids drug use evaluation
»
5. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required) » - a. Acthar - revision b. Oxervate - new criteria c. Palforzia - new criteria d. Spravato - new criteria
5. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required) »
a. Acthar - revision b. Oxervate - new criteria
c. Palforzia - new criteria
d. Spravato - new criteria
»
6. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Justin Pedigo, Pharm. D., The University of Texas at Austin College of Pharmacy (vote required) » - a. Immune globulins b. Non-sedating antihistamines c. Oral fluoroquinolones d. Oral/Rectal NSAIDs e. Rifaximin (Xifaxan®) f. Sickle cell disease products g. Skeletal muscle relaxants
6. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Justin Pedigo, Pharm. D., The University of Texas at Austin College of Pharmacy (vote required) »
a. Immune globulins b. Non-sedating antihistamines
c. Oral fluoroquinolones
d. Oral/Rectal NSAIDs
e. Rifaximin (Xifaxan®)
f. Sickle cell disease products
g. Skeletal muscle relaxants
»
Items 7 & 8 » - 7. Next meeting date: October 23, 2020 8. Adjourn
Items 7 & 8 »
7. Next meeting date: October 23, 2020 8. Adjourn
